Sean Colm Turner
Inventor
Stats
- 22 US patents issued
- 31 US Applications filed
- most recent filing
This is official USPTO record data
Details
- 22 US Patents Issued
- 31 US Applications Filed
- 102 Total Citation Count
- Oct 4, 2017 Most Recent Filing
- Jan 15, 1998 Earliest Filing
Work History
| Patent Owner | Applications Filed | Year |
|---|---|---|
| Abbott Laboratories | 2
1 | 2007
2010 |
| ABBVIE DEUTSCHLAND GMBH & CO KG | 7
10 2 2 6 2 3 3 3 1 | 2007
2008 2009 2010 2011 2012 2013 2014 2015 2017 |
| ABBOTT GMBH & CO. KG | 1
1 | 2008
2010 |
| ABBVIE INC. | 1
2 2 1 | 2007
2013 2014 2017 |
| CIBA SPECIALTY CHEMICALS CORPORATION | 3
1 2 | 1998
2000 2001 |
Inventor Addresses
| Address | Duration |
|---|---|
| Berkeley, CA | Jul 11, 00 - Jun 25, 02 |
| Berkeley, CA, US | Oct 04, 01 - Jun 20, 02 |
| Evanston, IL | Dec 03, 02 - Apr 22, 03 |
| Ludwigshafen, DE | Jun 03, 10 - Oct 16, 18 |
| Mannheim, Baden-Wurttemberg, DE | May 21, 09 - May 21, 09 |
| Mannheim, DE | Jun 04, 09 - Jan 02, 18 |
| WIESBADEN, DE | May 29, 14 - Jun 25, 15 |
| Wiesbaden, DE | Oct 17, 17 - Oct 17, 17 |
Technology Profile
| Technology | Matters | |
|---|---|---|
| A61K: | PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES | 18 |
| A61P: | THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS | 14 |
| C07C: | ACYCLIC OR CARBOCYCLIC COMPOUNDS | 2 |
Patents / Publication
| Patents / Publication # | Year of Publication / Issued | Title | Citations |
|---|---|---|---|
| 10100048 | 2018 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | 0 |
| 2018/0030,033 | 2018 | NOVEL INHIBITOR COMPOUNDS OF PHOSPHODIESTERASE TYPE 10A | 0 |
| 9856234 | 2018 | Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors | 0 |
| 9790203 | 2017 | Inhibitor compounds of phosphodiesterase type 10A | 1 |
| 9540370 | 2017 | Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors | 0 |
We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level.
>
Upgrade to our Level for up to -1 portfolios!.